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Coronary heart disease (CHD) remains the leading cause of death among American women.
Numerous differences exist between younger and older women and between women and men
with respect to the pathology of CHD and its incidence and prevalence over the life cycle.
Differences in lipoprotein levels and lipid fractions play an important role in CHD risk.
Hormonal influences on lipoprotein levels in women are complex, change throughout the life
span, and are influenced by the administration of oral contraceptives and hormone
replacement therapy. Women with obesity, metabolic syndrome, or diabetes have lipid
profiles that adversely affect CHD risk. To date, no randomized trials testing the impact of
lifestyle changes on lipoprotein levels and subsequent CHD events in non-institutionalized
women have been performed, and women have not been well represented in clinical end point
trials of pharmacologic lipid-lowering therapy. Available evidence suggests that lipid-
lowering therapy with statins does provide benefit in reducing the risk of coronary events in
women; however, women remain undertreated, and more data are needed to determine
optimal cardiovascular prevention and treatment in this population. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.0892005;46:1628–35) © 2005 by the American College of Cardiology Foundation
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poronary heart disease (CHD) is the single leading cause of
eath among American women, as it is among American
en (1), even though CHD is less common and occurs later
n life in women than men (2). In 2002, the prevalence of
yocardial infarction (MI) in women was 3 million, and 3.3
illion women had a history of angina pectoris; overall
revalence of CHD was 5.9 million (2). Every year, 345,000
omen suffer a new or recurrent MI, and 241,600 women
ie of an MI (2). From 1970 to 2001, hospital discharges
elated to CHD for women increased 47% (2). Clearly,
omen, and particularly postmenopausal women, remain at
igh risk for coronary events—at least in part because
omen have been under-represented in clinical outcomes
rials, tend to be undertreated in the clinical setting, and
ight be misdiagnosed when their presenting symptoms
iffer from those of men (3).
ENDER DIFFERENCES IN
RESENTATION OF CORONARY ATHEROSCLEROSIS
oronary atherosclerosis starts in early childhood and in-
reases with age (4). A close correlation exists between
raditional cardiovascular risk factors and extent of athero-
clerotic involvement in male and female children and
dolescents that is analogous to that seen among adults.
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005, accepted May 2, 2005.oreover, atherosclerosis is most pronounced among indi-
iduals with multiple coexistent risk factors (4). Autopsy
ata from the Pathobiological Determinants of Atheroscle-
osis in Youth Research Group show that girls and young
omen tend to have less extensive atherosclerotic involve-
ent than their age-matched male counterparts (5). Among
oung adults, women have lesser degrees of coronary calci-
cation than men (6). Coronary calcification increases with
ge in both genders, but women lag behind men by about 10
o 15 years (7). Numerous coronary angiographic studies
ave shown lesser degrees of epicardial coronary artery
isease among women than among similarly aged men. This
ender discrepancy holds true after stratification by symp-
oms (typical angina, atypical angina, non-anginal chest
ain) (8) and in populations without symptoms of CHD
ho undergo coronary angiography in preparation for val-
ular surgery (9).
Angiographic and intravascular ultrasound studies show
hat women have smaller coronary arteries than men, even
fter correcting for body surface area (10,11); however, the
emodeling that occurs in coronary arteries as atheroscle-
otic plaque accumulates seems to be similar in women and
en (12). The ultrasound appearance of lesions slated for
ercutaneous intervention is similar in terms of plaque
urden, calcium content, and eccentricity (13). Data on
ender differences in plaque composition are limited. Eggen
t al. (14) reported in 1965 that plaques among women were
ess calcified than those among men. An intravascular
ltrasound study by Rasheed et al. (15) showed a trend
oward a greater proportion of hard plaques in men com-
ared with women (47% vs. 33%, p  0.06). In an autopsy
tudy of individuals40 years of age who died1 year after
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November 1, 2005:1628–35 Dyslipidemia and CHD in Womenoronary artery bypass graft, women had greater amounts of
ellular fibrous tissue and lesser amounts of dense fibrous
issue in both native coronary arteries and saphenous vein
rafts, although there were no gender differences in the
everity of obstruction or in the amount of intracellular lipid
r degree of inflammatory infiltration (16). The same group
eported large amounts of lipid-containing foam cells and
elative lack of acellular scar tissue in women 40 years of
ge (17).
Although patients of both genders with MIs tend to
resent with thrombotic coronary occlusions, the precipi-
ating events might be different. In at least one autopsy
eries, women were twice as likely as men to have plaque
rosion (37% vs. 18%), whereas plaque rupture was more
ommon among men than women (82% vs. 63%) (18).
mong sudden death victims, Burke et al. (19) found that
cute coronary thrombosis was related to plaque erosion
mong younger, presumably premenopausal women,
hereas plaque rupture with superimposed thrombus or
ealed infarct without thrombosis was the characteristic
nding among older, presumably postmenopausal women.
isk profiles in these women also differed: smoking was
ssociated with plaque erosion, glycosylated hemoglobin
ith stable plaque and healed infarct, higher total choles-
erol with plaque rupture, and hypertension with stable
laque and healed infarct (19). The authors suggested that
isk modification might be more effective in younger and
lder women if it targeted different mechanisms of plaque
nstability. Whether gender differences in plaque pathology
re also present among patients with nonfatal acute coronary
yndromes or MIs is unknown.
IPOPROTEINS THROUGHOUT THE LIFESPAN
ipoprotein levels in prepubertal girls and boys are similar.
he association between lipoprotein levels in childhood and
dulthood is strongest for low-density lipoprotein (LDL)
holesterol but also significant for high-density lipoprotein
HDL) cholesterol and triglycerides (20). Gender differ-
nces in HDL cholesterol levels and HDL particle size
merge at puberty, and women maintain approximately
Abbreviations and Acronyms
ALLHAT  Antihypertensive and Lipid-Lowering Trial
to Prevent Heart Attack
ATP III  Third Report of the Adult Treatment
Panel
CHD  coronary heart disease
CVD  cardiovascular disease
HDL  high-density lipoprotein
HERS  Heart and Estrogen/progestin Replacement
Study
LDL  low-density lipoprotein
Lp(a)  lipoprotein(a)
MI  myocardial infarction
RLP  remnant-like particle0-mg/dl higher HDL cholesterol levels than men through- rut their lifetime (21–24). This gender difference in HDL
holesterol levels is maintained even in men and women
ith CHD, who tend to have lower HDL cholesterol levels
han persons without CHD (25). A substantial proportion
f women with CHD have HDL cholesterol levels of 60
g/dl, which is considered “protective” against CHD de-
elopment (23,26). Levels of LDL cholesterol and non-
DL cholesterol are lower in young and middle-aged
omen than in age-matched men, but the reverse is true
fter menopause (23,27). Interestingly, LDL particle num-
er remains lower in women than in men throughout their
ifetime (28). Paralleling the age-related increase in LDL-
holesterol in women, lipoprotein(a) (Lp[a]) also increases
s women grow older, whereas levels remain constant in
en (29).
remenopause. Hormonal influences on lipoprotein levels
n women are complex (30). In premenopausal women,
ipoprotein concentrations vary throughout the menstrual
ycle, with substantial heterogeneity among individuals and
tudies (31). Parous women tend to have lower HDL
holesterol levels than nulliparous women (32). Effects of
ontraceptive preparations vary, depending on estrogen
ose, progestin dose, androgenicity of the progestin, and
oute of administration (33–35). Increases in triglycerides
p to 57%, accompanied by decreases in LDL particle size,
ave been reported with oral contraceptives, whereas
hanges in LDL and HDL cholesterol levels tend to be of
maller magnitude (33–35). Although current oral contra-
eptive use is associated with increased cardiovascular risk,
specially among smokers, such an increase in risk is not
pparent among past users of oral contraceptives (36,37).
ostmenopause. It is well known that total cholesterol
evels increase at menopause (38–40). The LDL particle
istribution shifts toward smaller denser particles and LDL
holesterol levels tend to rise, although this increase is not
een in all studies (41–45). Decreases in HDL2 particles
ave been reported, but HDL cholesterol levels overall tend
o remain constant (43–45). Postmenopausal women tend
o have greater postprandial rises of lipoprotein levels after
tandardized fat meals than premenopausal women, even
fter taking the fasting triglyceride concentration into ac-
ount (46).
ffects of hormone therapy. Oral postmenopausal hor-
one therapy decreases LDL cholesterol and Lp(a) levels
ut increases HDL cholesterol and triglyceride levels (47–
9). The increase in triglyceride levels is most pronounced
ith estrogen monotherapy and might be associated with
riglyceride enrichment of LDL particles and adverse
hanges in LDL particle size and atherogenicity (47,50–
2). Progestin therapy tends to attenuate this triglyceride
ise, but it also blunts the rise in HDL cholesterol associated
ith oral estrogen supplementation (47). Estrogen receptor
olymorphisms are closely linked to the magnitude of the
DL cholesterol response to hormone replacement therapy
53). Apolipoprotein E phenotype might also modulate the
esponse to hormone therapy, but the heterogeneity seen in
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Dyslipidemia and CHD in Women November 1, 2005:1628–35linical practice is more likely related to differences in the
aseline lipid profile, dietary variations, and variable com-
liance (54). Lipoprotein effects are attenuated when lower-
ose formulations are used (55). Changes in lipid profiles
ith hormone therapy have not translated into beneficial
hanges in angiographic coronary artery disease nor into
mproved cardiovascular outcomes, at least in part related to
ro-thrombotic and pro-inflammatory effects of hormone
herapy (56). Hormone therapy is not recommended for
ardiovascular disease (CVD) prevention in women (3).
In short-term studies, transdermal estrogen supplemen-
ation is lipid-neutral. Longer-term transdermal therapy
ight result in LDL cholesterol lowering without signifi-
antly affecting HDL cholesterol and triglyceride levels
57). Beneficial changes in the lipid profile have also been
eported with transdermal continuous combined therapy;
ut transdermal therapy did not affect Lp(a) levels (58).
Selective estrogen receptor modulators have less pro-
ounced effects on the lipid profile than oral hormone
herapy. In a three-year trial, raloxifene did not affect HDL
holesterol levels, but lowered LDL cholesterol levels by
pproximately 10% and increased triglyceride levels by up to
% (59). In the much larger Multiple Outcomes of Ralox-
fene Evaluation trial, LDL cholesterol levels decreased by
% to 9% and triglycerides increased by up to 1.5%, whereas
DL cholesterol did not change (60). Although an analysis
f safety data in this trial suggested cardiovascular benefits
f raloxifene in women at high risk for CVD or with
stablished CHD, the investigators concluded that these
ndings must be confirmed by an adequately powered,
andomized trial with cardiovascular events as predefined
utcomes (60).
ipoproteins in obesity and diabetes. Many studies doc-
ment adverse changes in the lipid profile among obese
omen and women with the metabolic syndrome or diabe-
es mellitus (61). These adverse lipid changes are character-
zed by a greater prevalence of LDL phenotype B, lower
DL cholesterol levels, and higher triglyceride levels (62).
dverse lipoprotein changes associated with diabetes tend
o be more pronounced in women than in men and might
ediate the greater adverse prognostic impact of diabetes
mong women, which has been consistently demonstrated
61,63–65).
MPACT OF DYSLIPIDEMIA IN WOMEN
umerous traditional and emerging risk factors contribute
o the development of CHD in men and women and have
een reviewed in detail elsewhere (3). This review will focus
n the impact of dyslipidemia only.
Many observational studies show that CHD risk in-
reases with increases in total and LDL cholesterol levels
nd decreases with increases in HDL cholesterol levels in
oth genders, but the relative importance of these lipopro-
ein fractions might differ by gender (66–71). Levels of
DL cholesterol and triglycerides appear to be more closely aelated to CHD risk among women than men, whereas
DL cholesterol appears to be a more potent predictor
mong men (69,70). Non-HDL cholesterol appears to be a
etter measure of CHD risk in women than in men (72).
lthough the relative risk of CHD due to lipid abnormal-
ties is higher in younger than older women, the attributable
isk is higher in the older age groups (73). Abnormal
ipoproteins predict not only incident CHD among previ-
usly healthy women, but also recurrent events among those
ith prevalent CHD (74,75).
Smaller than average LDL particle size and LDL pattern
seem to be associated with the development of premature
HD in younger women, even after LDL cholesterol levels
nd other risk factors are taken into account; however, the
ssociation is not independent of HDL cholesterol levels,
riglyceride levels, and body mass index (76). Among older
omen, LDL size and LDL phenotype might not relate to
ardiovascular outcomes (77).
The role of triglyceride-rich remnant particles in the
evelopment and progression of CHD in women remains
nclear. Remnant-like particle (RLP) cholesterol and tri-
lyceride levels are higher in postmenopausal than in pre-
enopausal women and in women with CHD than in
ealthy women (78,79). The RLP cholesterol was an
ndependent risk factor for CVD among women enrolled in
he Framingham Heart Study (80). Although RLP choles-
erol has been linked to progression of coronary and
ein-graft atherosclerosis in men (81), such a relationship
as not seen for either RLP cholesterol or triglycerides in the
omen’s Angiographic Vitamin and Estrogen study, an
ngiographic trial of hormone and antioxidant therapy in
ostmenopausal women with CHD (82). Remnant levels in
his cohort were very high on average but did not relate to
rogression of CHD or to clinical events (82).
Elevated Lp(a) levels seem to be more strongly related to
HD events than to severity of coronary artery disease in
oth genders. In the Framingham study, elevated Lp(a)
evels in women strongly predicted incident MI but also
orrelated with claudication and development of cerebro-
ascular disease (83). Elevated Lp(a) also strongly predicts
ecurrent events among women with CHD (49). A post-
oc subgroup analysis from the Heart and Estrogen/
rogestin Replacement Study (HERS) study suggested
otential benefit of hormone therapy among women with
igh Lp(a) levels, but this finding remains to be confirmed
n a prospective randomized trial (49).
MPACT OF LIPID-LOWERING THERAPY IN WOMEN
tabilization and/or regression of coronary lesions with
igorous lifestyle modification have been shown in men with
oronary disease (84,85) but not in women, and, to date, no
rials showing the impact of lifestyle changes on CHD
vents in non-institutionalized women have been published.
t is clear, however, that weight management, adherence to
healthy diet, and regular physical activity have beneficial
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November 1, 2005:1628–35 Dyslipidemia and CHD in Womenffects on the lipid profile (and on other risk factors) in
omen as well as men. Lifestyle modification should thus
e recommended to all women with dyslipidemia as out-
ined in current prevention guidelines (3,86).
Lipoprotein changes in response to pharmacologic lipid-
owering therapy seem to be similar in magnitude and
irection in men and women (86,87). The cardiovascular
enefits of lipid-lowering therapy in women are less clear
han in men, because women make up a minority of study
articipants in most clinical end point trials, and subgroup
esults by gender are often not reported. Outcomes data in
omen with lipid-lowering medications other than statins
re exceedingly limited (88).
Comparable angiographic benefit in women and men
ith familial hypercholesterolemia treated with lovastatin
as shown by Kane et al. (89) in 1990. In a meta-analysis by
aRosa et al. (90) of the early statin trials with clinical end
oints, women and men achieved similar reductions in
ajor coronary events, and the authors calculated that the
umber needed to treat was 31 for women and 27 for men.
n updated meta-analysis of statin end point trials by
alsh and Pignone (88) included newer trials, such as the
ntihypertensive and Lipid-Lowering Treatment to Pre-
ent Heart Attack Trial (ALLHAT), the lipid-lowering
rm of the Anglo-Scandinavian Cardiac Outcomes Trial,
nd the Heart Protection Study, as well as studies dating
ack to the early 1970s and 1980s that used colestipol,
holestyramine, and clofibrate as the therapeutic interven-
ions. The Heart Protection Study is particularly important
n this context, because it enrolled over 5,000 women, more
omen than in all the other previous trials combined, and
howed that major vascular events were significantly reduced
rom 17.7% to 14.4% (relative risk reduction: 18.6%) (91).
he authors concluded that women with CVD who are
reated with statins achieve a 20% to 30% reduction in
HD mortality, non-fatal MI, revascularization, and CHD
vents, but no reduction in total mortality. The number
eeded to treat to prevent one event was estimated at 26. In
he Treating to New Targets study which compared 10 mg
f atorvastatin with 80 mg of atorvastatin in patients with
table CHD and was published after this meta-analysis,
ajor cardiovascular events were reduced 22% in the high-
ose group without statistically significant interaction by
ender; there was no reduction in total mortality with more
ntensive therapy (92).
cute coronary syndromes. Statin trials in patients with
cute coronary syndromes were not included in the updated
eta-analysis. In the Pravastatin or Atorvastatin Evaluation
nd Infection Therapy study, a 16% reduction in the
ombined end point (death from any cause, MI, docu-
ented unstable angina requiring re-hospitalization, revas-
ularization, and stroke) was achieved with aggressive lipid-
owering therapy, which lowered LDL cholesterol to an
n-trial level of 62 mg/dl (93). Women made up only 22%
f study subjects, but a predefined subgroup analysis sug-
ested that the benefit of aggressive lipid lowering in this retting was consistent across gender subgroups (93). The
nly other randomized trial of statin therapy in this popu-
ation (the A to Z Trial) did not show a significant benefit
f early aggressive therapy, but point estimates (a non-
ignificant 11% reduction in events) were identical in men
nd women (94).
rimary prevention. Among women without CVD, Walsh
nd Pignone (88) found no evidence of a mortality benefit
r any decrease in CHD mortality, non-fatal MI, revascu-
arization, or CHD events; however, when ALLHAT
which was unblinded and had a 32% drop-in of lipid-
owering therapy in the placebo group) was excluded from
he analysis, they found a significant 23% reduction in
HD events (summary risk ratio, 0.77; 95% confidence
nterval [CI], 0.64 to 0.94). The authors concluded that
here was insufficient evidence to determine whether lipid-
owering therapy was effective in reducing CHD events in
omen without CVD (88). The Collaborative Atorvastatin
iabetes Study, a trial of statin therapy among patients
32% women) with diabetes but without known CVD, was
ublished three months after the meta-analysis (95). The
rial was terminated two years earlier than expected, because
he prespecified early stopping criterion for efficacy had been
et. Cardiovascular events were reduced by 37% (95% CI,
52 to 17; p  0.001) over a median of 3.9 years of
ollow-up, without heterogeneity by age, gender, baseline
ipid profile, hypertension, or smoking.
The Third Report of the Adult Treatment Panel (ATP
II) of the National Cholesterol Education Program does
ot recommend different treatment guidelines for men and
omen, but their approach to considering drug therapy for
iddle-aged women with 10% 10-year risk for CHD is
omewhat more cautious than it is for middle-aged men in
he same risk category (86). The Expert Panel acknowl-
dged that recommendations for women without CVD
ere based on extrapolation of benefit from men at similar
isk (86).
tatin therapy. Consistent with the clinical trials evidence
ase, the most commonly used drugs for lipid lowering are
tatins. Comparative efficacy of currently available statins is
hown in Table 1 (96–98). Statins are generally well
olerated, with a low incidence of liver abnormalities and
uscle toxicity, but important drug interactions between
tatins and other drugs have been reported, particularly with
tatins metabolized by the CYP 3A4 system (Table 2)
96–98). Statins should not be used in women who are
regnant, are trying to become pregnant, or who are
reast-feeding. The reader is referred to the ATP III
uidelines for detailed information on the non-statin drugs
urrently on the market (86).
NDERTREATMENT AND TREATMENT DISPARITIES
n the HERS study, which recruited postmenopausal women
ith CHD from 1993 to 1994, 47% of women were
eceiving lipid-lowering therapy, but only 37% had met the
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Dyslipidemia and CHD in Women November 1, 2005:1628–35DL cholesterol goal of 130 mg/dl as recommended by
he 1988 ATP guidelines, and only 9% had met the LDL
holesterol goal of 100 mg/dl as recommended by the
993 guidelines (99). Only 7% of HERS women started
tatin therapy during the first year of follow-up, despite
ubstantial publicity surrounding the new and more aggres-
ive ATP II LDL cholesterol goals at that time. Under-
reatment was more pronounced among black women than
mong white women enrolled in the trial (100). Miller et al.
101) reported on treatment rates among patients in the
rospective Randomized Evaluation of the Vascular Effects
f Norvasc Trial, who were enrolled between 1994 and
997. During that period, the proportion of women who
chieved an LDL cholesterol goal of 100 mg/dl increased
rom 6% to 12%, whereas the proportion of men increased
rom 17% to 31% (101). Data collected from 1998 to 1999
rom the National Registry of Myocardial Infarction
howed that women were less likely to receive lipid-
owering therapy at hospital discharge than men (multivar-
ate odds ratio for men 1.03, 95% CI, 1.00 to 1.06), but less
han one-third of patients of both genders were discharged
n treatment (102). In the Women’s Ischemia Syndrome
valuation study, which enrolled patients between 1996 and
997, only 24% of women with a history of CHD, 56% of
igh-risk women, and 88% of low-risk women had met
heir respective LDL cholesterol goals. All women under-
ent diagnostic coronary angiography, but angiography
able 1. Comparative Efficacy and Pharmacology of the Currentl
Drug
Changes in %
Dosage Form
Tablets, mg2TC 2LDL-C 1HDL-C 2TG
torvastatin 25–45 26–60 5–13 17–53 10, 20, 40, 80
luvastatin 16–27 22–36 3–11 12–25 20, 40, 80
ovastatin 16–34 21–42 2–10 6–27 10, 20, 40
ravastatin 16–25 22–34 2–12 15–24 10, 20, 40, 80
osuvastatin 33–46 45–63 8–14 10–35 5, 10, 20, 40
imvastatin 19–36 26–47 8–16 12–34 5, 10, 20, 40, 8
able 1 is based on composite data from references 96–98. *Standard dose is a dose
CYP  cytochrome P; HDL-C  high-density lipoprotein cholesterol; LDL-
1/2  half-life.
able 2. Important Drug Interactions With Selected Statins
ipid-lowering agents
Fibrates (especially gemfibrozil), niacin
ardiovascular agents
Warfarin, digoxin, verapamil, amiodarone
mmunosuppressive agents
Tacrolimus, cyclosporine
gents to treat infections
Fluconazole, itraconazole, ketoconazole
Erythromycin, clarithromycin
HIV protease inhibitors
sychoactive agents
Nefazodone, venlafaxine, fluoxetine, sertraline, benzodiazepines
thers
Antihistamines
Grapefruit juiceBable 2 is based on composite data from references 96–98.
HIV  human immunodeficiency virus.esults did not impact therapy in women with newly
iagnosed coronary artery disease or in those whose diag-
osis was confirmed (103).
Reasons for undertreatment are complex and reflect
hysician and patient preferences as well as environmental
actors such as access to care and cost of medication.
urrent guidelines for cardiovascular risk prevention in
omen emphasize the importance of achieving recom-
ended lipoprotein goals (3). A recent report from the
ardiac rehabilitation setting suggests that treatment rates
mong women with CHD have improved, because 49% of
omen who completed cardiac rehabilitation between 1996
nd 2003 achieved their LDL cholesterol goal of 100
g/dl (104). It is not known whether the situation has
mproved in less-structured care settings or among women
ithout known CVD who, nevertheless, are at high risk for
ubsequent events.
UMMARY AND FUTURE DIRECTIONS
oronary heart disease is the most important cause of death
mong American women and is responsible for disability
nd poor quality of life in many women. Dyslipidemia is an
mportant risk factor for the initiation and progression of
therosclerosis and is strongly associated with cardiovascular
vents. Emphasis on a healthy lifestyle should begin in
hildhood and continue throughout life. Although the
enefits of lipid-lowering therapy appear to be clear in
omen with CVD, more data are needed for women
ithout CVD. Clinical trials of lipid lowering, to date, have
xclusively used a strategy focused on lowering LDL cho-
esterol, which might not be optimal among those women in
hom low levels of HDL cholesterol or elevated triglycer-
des appear to be as strongly or more strongly related to
ubsequent CHD. Whether outcomes among women will
mprove when treatment strategies are geared toward a more
ggressive and comprehensive modification of lipoprotein
rofiles remains to be determined.
eprint requests and correspondence:Dr. Vera Bittner, Division
f Cardiovascular Disease, 701 19th Street South-LHRB 310,
ailable Statins
tandard
ose, mg* Metabolism
Protein
Binding, % T1/2, h Hydrophilic
10 CYP3A4 98 13–30 No
40–80 CYP2C9 98 0.5–3.0 No
40 CYP3A4 95 2–4 No
40 Sulfation 43–67 2–3 Yes
5–10 CYP2C9, CYP2C19 88 19 Yes
20–40 CYP3A4 95–98 1–3 No
ill achieve 30% to 40% LDL-C lowering as recommended by Grundy et al. (97).
low-density lipoprotein cholesterol; TC  total cholesterol; TG  triglycerides;y Av
S
D
0
that wirmingham, Alabama 35294-0007. E-mail: vbittner@uab.edu.
R1633JACC Vol. 46, No. 9, 2005 Bittner
November 1, 2005:1628–35 Dyslipidemia and CHD in WomenEFERENCES
1. American Heart Association. Heart Disease and Stroke Statistics—2005
Update. Available at: http://www.americanheart.org/downloadable/
heart/1105390918119HDSStats2005Update.pdf. Accessed January 26,
2005.
2. American Heart Association. Statistical Fact Sheet: Populations. Women
and Cardiovascular Diseases: Statistics. Available at: http://www.
americanheart.org/downloadable/heart/1104938287787FS10WM05rev.
pdf. Accessed January 26, 2005.
3. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines
for cardiovascular disease prevention in women. Circulation 2004;
109:672–93.
4. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE,
Wattigney WA, for the Bogalusa Heart Study. Association between
multiple cardiovascular risk factors and atherosclerosis in children and
young adults. N Engl J Med 1998;338:1650–6.
5. McGill HC Jr., McMahan A, Zieske AW, et al., for the Pathobio-
logical Determinants of Atherosclerosis in Youth (PDAY) Research
Group. Associations of coronary heart disease risk factors with the
intermediate lesion of atherosclerosis in youth. Arterioscler Thromb
Vasc Biol 2000;20:1998–2004.
6. Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors
measured in childhood and young adult life are associated with
coronary artery calcification in young adults: the Muscatine Study.
J Am Coll Cardiol 1996;27:277–84.
7. Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT.
Age and gender distribution of coronary artery calcium detected by
electron beam tomography in 35,246 adults. Am J Cardiol 2001;87:
1335–9.
8. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic preva-
lence of high-risk coronary artery disease in patient subsets (CASS).
Circulation 1981;64:360–7.
9. Enriquez-Sarano M, Klodas E, Garratt KN, Bailey KR, Tajik AJ,
Holmes DR Jr. Secular trends in coronary atherosclerosis: analysis in
patients with valvular regurgitation. N Engl J Med 1996;335:316–22.
10. Dodge JT Jr., Brown BG, Bolson EL, Dodge HT. Lumen diameter
of normal human coronary arteries: influence of age, sex, anatomic
variation, and left ventricular hypertrophy or dilation. Circulation
1992;86:232–46.
11. Sheifer SE, Canos MR, Weinfurt KP, et al. Sex differences in
coronary artery size assessed by intravascular ultrasound. Am Heart J
2000;139:649–53.
12. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP.
Remodeling of coronary arteries in human and nonhuman primates.
JAMA 1994;271:289–94.
13. Kornowski R, Lansky AJ, Mintz GS, et al. Comparison of men
versus women in cross-sectional area luminal narrowing, quantity of
plaque, presence of calcium in plaque, and lumen location in coronary
arteries by intravascular ultrasound in patients with stable angina
pectoris. Am J Cardiol 1997;79:1601–5.
14. Eggen DA, Strong JP, McGill HC Jr. Coronary calcification:
relationship to clinically significant coronary lesions and race, sex, and
topographic distribution. Circulation 1965;32:948–55.
15. Rasheed Q, Nair R, Sheehan H, Hodgson JM. Correlation of
intracoronary ultrasound plaque characteristics in atherosclerotic
coronary artery disease patients with clinical variables. Am J Cardiol
1994;73:753–8.
16. Mautner SL, Lin F, Mautner GC, Roberts WC. Comparison in
women versus men of composition of atherosclerotic plaques in native
coronary arteries and in saphenous veins used as aortocoronary
conduits. J Am Coll Cardiol 1993;21:1312–8.
17. Dollar AL, Kragel AH, Fernicola DJ, Waclawiw MA, Roberts WC.
Composition of atherosclerotic plaques in coronary arteries in women
40 years of age with fatal coronary artery disease and implications
for plaque reversibility. Am J Cardiol 1991;67:1223–7.
18. Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major
substrate for coronary thrombosis in acute myocardial infarction.
Heart 1999;82:269–72.
19. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R.
Effect of risk factors on the mechanism of acute thrombosis and
sudden coronary death in women. Circulation 1998;97:2110–6.20. Bao W, Srinivasan SR, Wattigney WA, Bao W, Berenson GS.
Usefulness of childhood low-density lipoprotein cholesterol level inpredicting adult dyslipidemia and other cardiovascular risks: the
Bogalusa Heart Study. Arch Intern Med 1996;156:1315–20.
21. National Heart, Lung, and Blood Institute. The Lipid Research
Clinics Population Studies Data Book: Volume 1—The Prevalence
Study. Bethesda, MD: U.S. Department of Health and Human
Services, Public Health Service, National Institutes of Health, NIH
Publication No. 80-1527, July 1980.
22. Freedman DS, Bowman BA, Srinivasan SR, Berenson GS, Otvos
JD. Distribution and correlates of high-density lipoprotein subclasses
among children and adolescents. Metabolism 2001;50:370–6.
23. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. Second report of the Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults. Available at: http://www.nhlbi.nih.gov/guidelines/
cholesterol/atp3_rpt.htm. Accessed September 6, 2005.
24. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP.
Population frequency distributions of HDL, HDL(2), and HDL(3)
cholesterol and apolipoproteins A-I and B in healthy men and
women and associations with age, gender, hormonal status, and sex
hormone use: the Stanford Five City Project. Prev Med 2000;31:
335–45.
25. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel.
Lipids and lipoproteins in symptomatic coronary heart disease:
distribution, intercorrelations, and significance for risk classification
in 6,700 men and 2,500 women. Circulation 1992;86:839–46.
26. Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, Stefanick
ML. Correlates of high HDL cholesterol among women with
coronary heart disease. Am Heart J 2000;139:288–96.
27. Gardner CD, Winkleby MA, Fortmann SP. Population frequency
distribution of non–high-density lipoprotein cholesterol (Third Na-
tional Health and Nutrition Examination Survey [NHANES III],
1988–1994). Am J Cardiol 2000;86:299–304.
28. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender,
and menopausal status on plasma low density lipoprotein cholesterol
and apolipoprotein B levels in the Framingham Offspring Study. J
Lipid Res 1994;35:779–92.
29. LaRosa JC. Lipoproteins and CAD risk in women. J Myocardial
Ischemia 1991;3:35–42.
30. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism.
Curr Opin Lipidol 1994;5:236–40.
31. Gosland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins
and atherosclerosis: prevailing assumptions and outstanding ques-
tions. Am Heart J 1997;114:1467–503.
32. van Stiphout WA, Hofman A, de Bruijn AM. Serum lipids in young
women before, during, and after pregnancy. Am J Epidemiol 1987;
126:922–8.
33. Greenlund KJ, Webber LS, Srinivasan S, Wattigney W, Johnson C,
Berenson GS. Associations of oral contraceptive use with serum
lipids and lipoproteins in young women: the Bogalusa Heart Study.
Ann Epidemiol 1997;7:561–7.
34. Godsland IF, Crook D, Simpson R, et al. The effects of different
formulations of oral contraceptive agents on lipid and carbohydrate
metabolism. N Engl J Med 1990;323:1375–81.
35. Foulon T, Payen N, Laporte F, et al. Effects of two low-dose oral
contraceptives containing ethinylestradiol and either desogestrel or
levonorgestrel on serum lipids and lipoproteins with particular regard
to LDL size. Contraception 2001;64:11–6.
36. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives
and cardiovascular disease. Ann Intern Med 1998;128:467–77.
37. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens
CH. Past use of oral contraceptives and cardiovascular disease: a
meta-analysis in the context of the Nurses’ Health Study. Am J
Obstet Gynecol 1990;163:285–91.
38. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K.
Effects of menopause on trends of serum cholesterol, blood pressure,
and body mass index. Circulation 1996;94:61–6.
39. Hjortland MC, McNamara PM, Kannel WB. Some atherogenic
concomitants of menopause: the Framingham Study. Am J Epide-
miol 1976;103;304–11.
40. van Beresteijn EC, Korevaar JC, Huijbregts PC, Schouten EG,
Burema J, Kok FJ. Perimenopausal increase in serum cholesterol: a
10-year longitudinal study. Am J Epidemiol 1993;137:383–92.41. Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ.
Differences in low density lipoprotein subfractions and apolipopro-
1634 Bittner JACC Vol. 46, No. 9, 2005
Dyslipidemia and CHD in Women November 1, 2005:1628–35teins in premenopausal and postmenopausal women. J Clin
Endocrinol Metab 1988;67:30–5.
42. Carr MC, Kim KH, Zambon A, et al. Changes in LDL density
across the menopausal transition. J Invest Med 2000;48:245–50.
43. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Denerstein
L. Longitudinal study of risk factors for coronary heart disease across
the menopausal transition. Am J Epidemiol 2000;151:584–93.
44. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW,
Wing RR. Menopause and risk factors for coronary heart disease.
N Engl J Med 1989;321:641–6.
45. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P.
Influence of the perimenopause on cardiovascular risk factors and
symptoms of middle-aged healthy women. Arch Intern Med 1994;
154:2349–55.
46. van Beek AP, de Ruijter-Heijstek FC, Erkelens DW, de Bruin
TWA. Menopause is associated with reduced protection from post-
prandial lipemia. Arterioscler Thromb Vasc Biol 1999;19:2737–41.
47. The Writing Group for the PEPI Trial. Effects of estrogen or
estrogen/progestin regimens on heart disease risk factors in post-
menopausal women: the Postmenopausal Estrogen/Progestin Inter-
ventions (PEPI) trial. JAMA 1995;273:199–208.
48. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/
progestin Replacement Study (HERS) Research Group. Random-
ized trial of estrogen plus progestin for secondary prevention of
coronary heart disease in postmenopausal women. JAMA 1998;280:
605–13.
49. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin,
lipoprotein(a), and the risk of recurrent coronary heart disease events
after menopause. JAMA 2000;283:1845–52.
50. Legault C, Stefanick ML, Miller VT, Marcovina SM, Schrott HG.
Effect of hormone replacement therapy on the validity of the
Friedewald equation in postmenopausal women: the Postmenopausal
Estrogen/Progestins Interventions (PEPI) trial. J Clin Epidemiol
1999;52:1187–95.
51. Alexanderson P, Haarbo J, Christiansen C. Impact of combined
hormone replacement therapy on serum lipid metabolism: new
aspects. Gynecol Endocrinol 1997;11:281–8.
52. Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T. Estrogen-induced
small low density lipoprotein particles may be atherogenic in post-
menopausal women. J Am Coll Cardiol 2001;37:425–30.
53. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-
receptor polymorphisms and effects of estrogen replacement on
high-density lipoprotein cholesterol in women with coronary disease.
N Engl J Med 2002;346:967–74.
54. Tsuda M, Sanada M, Nakagawa H, Kodama I, Sakashita T, Ohama
K. Phenotype of apolipoprotein E influences the lipid metabolic
response of postmenopausal women to hormone replacement ther-
apy. Maturitas 2001;38:297–304.
55. Koh KK, Shin M-S, Sakuma I, et al. Effects of conventional or lower
doses of hormone replacement therapy in postmenopausal women.
Arterioscler Thromb Vasc Biol 2004;24:1516–21.
56. Seed M, Knopp RH. Estrogens, lipoproteins, and cardiovascular risk
factors: an update following the randomized placebo-controlled trials of
hormone-replacement therapy. Curr Opin Lipidol 2004;15:459–67.
57. Ory SJ, Field CS, Herrmann RR, Zinsmeister AR, Riggs BL. Effects
of long-term transdermal administration of estradiol on serum lipids.
Mayo Clin Proc 1998;73:735–8.
58. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S,
Proudler AJ. Randomized trial of effect of transdermal continuous
combined hormone replacement therapy on cardiovascular risk mark-
ers. Br J Haematol 2004;124:802–8.
59. Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of
raloxifene and conjugated equine estrogen on bone and lipids in
healthy postmenopausal women. Arch Intern Med 2004;164:871–9.
60. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and
cardiovascular events in osteoporotic postmenopausal women: four-
year results from the MORE (Multiple Outcomes of Raloxifene
Evaluation) randomized trial. JAMA 2002;287:847–57.
61. Barrett-Connor E, Giardina E-GV, Gitt AK, Gudat U, Steinberg
HO, Tschoepe D. Women and heart disease: the role of diabetes and
hyperglycemia. Arch Intern Med 2004;164:934–42.
62. Austin MA, Selby JV. LDL subclass phenotypes and the risk factors
of the insulin resistance syndrome. Int J Obes Relat Metab Disord
1995;19 Suppl 1:S22–6.63. Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr., et
al. Sex differences in the effect of diabetes mellitus on lipoprotein
triglyceride and cholesterol concentrations. N Engl J Med 1984;311:
953–9.
64. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity
and mortality in the sexes: a 26-year follow-up of the Framingham
population. Am Heart J 1986;111:383–90.
65. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences
in risk for coronary heart disease mortality associated with diabetes
and established coronary heart disease. Arch Intern Med 2003;163:
1735–40.
66. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30
years of follow-up from the Framingham Study. JAMA 1987;257:
2176–80.
67. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S,
Kannel WB. Incidence of coronary heart disease and lipoprotein
cholesterol levels: the Framingham Study. JAMA 1986;256:2835–8.
68. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart
disease prediction from lipoprotein cholesterol levels, triglycerides,
lipoprotein (a), apolipoproteins A-I and B, and HDL density
subfractions: the Atherosclerosis Risk in Communities (ARIC)
study. Circulation 2001;104:1108–13.
69. Brunner D, Weisbort J, Meshulam N, et al. Relation of serum total
cholesterol and high-density lipoprotein cholesterol percentage to the
incidence of definite coronary events: twenty-year follow-up of the
Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J
Cardiol 1987;59:1271–6.
70. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein
levels as predictors of cardiovascular death in women. Arch Intern
Med 1993;153:2209–16.
71. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical
implications of recent studies. N Engl J Med 1989;321:1311–6.
72. Cui Y, Blumenthal RS, Flaws JA, et al. Non–high-density lipopro-
tein cholesterol level as a predictor of cardiovascular disease mortality.
Arch Intern Med 2001;161:1413–9.
73. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne
GH, Harlan WR. Cholesterol and heart disease in older persons and
women: review of an NHLBI Workshop. Ann Epidemiol 1992;2:
161–76.
74. Kannel WB. Range of serum cholesterol values in the population
developing coronary artery disease. Am J Cardiol 1995;76:69C–77C.
75. Shlipak MG, Chaput LA, Vittinghoff E, et al., for the Heart and
Estrogen/progestin Replacement Study (HERS) Investigators. Lipid
changes on hormone therapy and coronary heart disease events in the
Heart and Estrogen/progestin Replacement Study (HERS). Am
Heart J 2003;146:870–5.
76. Kamigaki AS, Siscovick DS, Schwartz SM, et al. Low density
lipoprotein particle size and risk of early-onset myocardial infarction
in women. Am J Epidemiol 2001;153:939–45.
77. Mykkänen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL
size and risk of coronary heart disease in elderly men and women.
Arterioscler Thromb Vasc Biol 1999;19:2742–8.
78. Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K. The
effect of hormone replacement therapy on metabolism of lipoprotein
remnants in postmenopausal women. Maturitas 2000;34:75–82.
79. Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of
remnant-like lipoprotein particles in postmenopausal women with
and without coronary artery disease and in men with coronary artery
disease. Am J Cardiol 2001;88:1370–3.
80. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle
(RLP) cholesterol is an independent cardiovascular disease risk factor
in women: results from the Framingham Heart Study. Atheroscle-
rosis 2001;154:229–36.
81. Karpe F, Taskinen M-R, Nieminen MS, et al. Remnant-like lipopro-
tein particle cholesterol concentration and progression of coronary
and vein-graft atherosclerosis in response to gemfibrozil treatment.
Atherosclerosis 2001;157:181–7.
82. Bittner V, Tripputi M, Hsia J, Gupta H, Steffes M, for the WAVE
Investigators. Remnant-like lipoproteins, hormone therapy, and an-
giographic and clinical outcomes: the Women’s Angiographic Vita-
min & Estrogen trial. Am Heart J 2004;148:293–9.
83. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective
investigation of elevated lipoprotein (a) detected by electrophoresis
11
1
1
1
1635JACC Vol. 46, No. 9, 2005 Bittner
November 1, 2005:1628–35 Dyslipidemia and CHD in Womenand cardiovascular disease in women: the Framingham Heart Study.
Circulation 1994;90:1688–95.
84. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle
changes for reversal of coronary heart disease. JAMA 1998;280:
2001–7.
85. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of
leisure time physical activity in patients with coronary artery disease:
effects on cardiorespiratory fitness and progression of coronary
atherosclerotic lesions. J Am Coll Cardiol 1993;22:468–77.
86. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. Third report of the National Choles-
terol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III): final report. Circulation 2002;106:
3143–421.
87. Goldberg AC. A meta-analysis of randomized controlled studies on
the effects of extended-release niacin in women. Am J Cardiol
2004;94:121–4.
88. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in
women. JAMA 2004;291:2243–52.
89. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ.
Regression of coronary atherosclerosis during treatment of familial
hypercholesterolemia with combined drug regimens. JAMA 1990;
264:3007–12.
90. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary
disease: a meta-analysis of randomized controlled trials. JAMA
1999;282:2340–6.
91. Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial. Lancet
2002;360:7–22.
92. LaRosa JC, Grundy SM, Waters DD, et al., for the Treating to New
Targets (TNT) Investigators. Intensive lipid lowering with atorva-
statin in patients with stable coronary disease. N Engl J Med
2005;352:1425–35.
93. Cannon CP, Braunwald E, McCabe CH, et al., for the Pravastatin or
Atorvastatin Evaluation and Infection Therapy–Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus moderate
lipid lowering with statins after acute coronary syndromes. N Engl
J Med 2004;350:1495–504.
94. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a
delayed conservative simvastatin strategy in patients with acutecoronary syndromes: Phase Z of the A to Z trial. JAMA 2004;
292:1307–16.
95. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the
CARDS Investigators. Primary prevention of cardiovascular disease
with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin
Diabetes Study (CARDS): multicentre randomised placebo-
controlled trial. Lancet 2004;364:685–96.
96. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation
2004;110:886–92.
97. DeAngelis G. The influence of statin characteristics on their safety
and tolerability. Int J Clin Pract 2004;58:945–55.
98. Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordi-
nating Committee of the National Cholesterol Education Program.
Implications of recent clinical trials for the National Cholesterol
Education Program Adult Treatment Panel III Guidelines. Circula-
tion 2004;110:227–39.
99. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for
the HERS Research Group. Adherence to National Cholesterol
Education Program treatment goals in postmenopausal women with
heart disease: the Heart and Estrogen/progestin Replacement Study
(HERS). JAMA 1997;277:1281–6.
00. Jha AK, Varosy PD, Kanaya AM, et al. Differences in medical care
and disease outcomes among black and white women with heart
disease. Circulation 2003;108:1089–94.
01. Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD, for the
Prospective Randomized Evaluation of the Vascular Effects of
Norvasc Trial (PREVENT) Investigators. Sex bias and underutili-
zation of lipid-lowering therapy in patients with coronary artery
disease at academic medical centers in the United States and Canada.
Arch Intern Med 2000;160:343–7.
02. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA, for the
National Registry of Myocardial Infarction 3 Participants. Use of
lipid-lowering medications at discharge in patients with acute myo-
cardial infarction: data from the National Registry of Myocardial
Infarction 3. Circulation 2001;103:38–44.
03. Bittner V, Olson M, Kelsey SF, et al., for the WISE Investigators.
Effect of coronary angiography on use of lipid-lowering agents in
women: a report from the Women’s Ischemia Syndrome Evaluation
(WISE) study. Am J Cardiol 2000;85:1083–8.
04. Sanderson BK, Bittner V. Women in cardiac rehabilitation: out-
comes and identifying risk for drop-out. Am Heart J 2005. In press.
